Alex Thompson
Stock Analyst at Stifel
(1.80)
# 3,283
Out of 4,984 analysts
37
Total ratings
51.72%
Success rate
-3.05%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alex Thompson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DNTH Dianthus Therapeutics | Maintains: Buy | $52 → $65 | $37.47 | +73.47% | 2 | Sep 12, 2025 | |
| TVTX Travere Therapeutics | Maintains: Hold | $20 → $25 | $22.77 | +9.79% | 4 | Sep 12, 2025 | |
| ASND Ascendis Pharma | Maintains: Buy | $212 → $254 | $197.24 | +28.78% | 3 | Aug 8, 2025 | |
| CGEM Cullinan Therapeutics | Reinstates: Buy | $22 | $6.29 | +249.76% | 1 | Jun 11, 2025 | |
| KYMR Kymera Therapeutics | Reinstates: Buy | $55 | $48.78 | +12.75% | 1 | May 20, 2025 | |
| AVTX Avalo Therapeutics | Initiates: Buy | $36 | $9.76 | +268.85% | 1 | Mar 25, 2025 | |
| CRNX Crinetics Pharmaceuticals | Initiates: Buy | $60 | $34.10 | +75.95% | 1 | Mar 25, 2025 | |
| ORKA Oruka Therapeutics | Initiates: Buy | $49 | $14.90 | +228.86% | 1 | Oct 11, 2024 | |
| ARGX argenx SE | Maintains: Buy | $485 → $500 | $752.32 | -33.54% | 4 | Jun 24, 2024 | |
| SYRE Spyre Therapeutics | Reiterates: Buy | $36 → $54 | $14.82 | +264.37% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $6 → $2 | $2.34 | -14.53% | 5 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $69 | $53.26 | +29.55% | 2 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $2 → $1 | $1.84 | -45.65% | 4 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $18.66 | +114.36% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $320 | $17.63 | +1,715.09% | 1 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $34 | $15.29 | +122.37% | 2 | Jul 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $33 | $1.53 | +2,056.86% | 1 | Dec 14, 2022 |
Dianthus Therapeutics
Sep 12, 2025
Maintains: Buy
Price Target: $52 → $65
Current: $37.47
Upside: +73.47%
Travere Therapeutics
Sep 12, 2025
Maintains: Hold
Price Target: $20 → $25
Current: $22.77
Upside: +9.79%
Ascendis Pharma
Aug 8, 2025
Maintains: Buy
Price Target: $212 → $254
Current: $197.24
Upside: +28.78%
Cullinan Therapeutics
Jun 11, 2025
Reinstates: Buy
Price Target: $22
Current: $6.29
Upside: +249.76%
Kymera Therapeutics
May 20, 2025
Reinstates: Buy
Price Target: $55
Current: $48.78
Upside: +12.75%
Avalo Therapeutics
Mar 25, 2025
Initiates: Buy
Price Target: $36
Current: $9.76
Upside: +268.85%
Crinetics Pharmaceuticals
Mar 25, 2025
Initiates: Buy
Price Target: $60
Current: $34.10
Upside: +75.95%
Oruka Therapeutics
Oct 11, 2024
Initiates: Buy
Price Target: $49
Current: $14.90
Upside: +228.86%
argenx SE
Jun 24, 2024
Maintains: Buy
Price Target: $485 → $500
Current: $752.32
Upside: -33.54%
Spyre Therapeutics
Mar 26, 2024
Reiterates: Buy
Price Target: $36 → $54
Current: $14.82
Upside: +264.37%
Dec 18, 2023
Maintains: Hold
Price Target: $6 → $2
Current: $2.34
Upside: -14.53%
Dec 18, 2023
Maintains: Buy
Price Target: $66 → $69
Current: $53.26
Upside: +29.55%
Dec 18, 2023
Maintains: Hold
Price Target: $2 → $1
Current: $1.84
Upside: -45.65%
Sep 13, 2023
Reiterates: Buy
Price Target: $40
Current: $18.66
Upside: +114.36%
Aug 9, 2023
Initiates: Buy
Price Target: $320
Current: $17.63
Upside: +1,715.09%
Jul 18, 2023
Maintains: Buy
Price Target: $28 → $34
Current: $15.29
Upside: +122.37%
Dec 14, 2022
Initiates: Buy
Price Target: $33
Current: $1.53
Upside: +2,056.86%